Celltrion Secures FDA Approval for AVTOZMA® Biosimilar to ACTEMRA® with Both IV and SC Formulations

Celltrion announced that the U.S. Food and Drug Administration (FDA) has approved AVTOZMA® (CT-P47, tocilizumab-anoh) in both an intravenous (IV) ...

February 12, 2025 | Wednesday | News
CSL’s HEMGENIX® Delivers Long-Term Bleed Protection for Hemophilia B with Four-Year Data from HOPE-B Study

 Global biotechnology leader CSL announced the four-year results from the pivotal HOPE-B study confirming the long-term durability and safety of a one...

February 10, 2025 | Monday | News
Regeneron’s EYLEA HD® 8 mg Shows Promise for Retinal Vein Occlusion in Phase 3 QUASAR Trial

Regeneron Pharmaceuticals, Inc.announced the first presentation of positive results from the Phase 3 QUASAR trial investigating EYLEA HD® (afliber...

February 10, 2025 | Monday | News
AbbVie Wins FDA Nod for EMBLAVEO™, Tackling Antimicrobial-Resistant Infections

AbbVie announced that the U.S. Food and Drug Administration (FDA) has approved EMBLAVEO™ (aztreonam and avibactam), as the first and only fixed-...

February 10, 2025 | Monday | News
Genentech's Gazyva® Demonstrates Significant Improvement in Lupus Nephritis in Phase III REGENCY Trial

Genentech, a member of the Roche Group, announced that a detailed analysis of its Phase III REGENCY trial of Gazyva® (obinutuzumab) in people with acti...

February 10, 2025 | Monday | News
Partner Therapeutics Announces NEJM Publication of Phase 2 eNRGy Trial Results for Zenocutuzumab-Zbco (BIZENGRI®)

Partner Therapeutics, Inc. (PTx), a private, fully-integrated biotechnology company announced  that the New England Journal of Medicine (NEJ...

February 06, 2025 | Thursday | News
Zoetis Updates U.S. Label for Librela® (bedinvetmab) Following Post-Approval Experience

Zoetis Inc. announced that it has updated the U.S. label for Librela® (bedinvetmab injection), following its submission of a supplement to the U.S...

February 05, 2025 | Wednesday | News
Roche Announces FDA Approval of Susvimo® for Diabetic Macular Edema, Offering a Treatment with Fewer Injections

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced  that the US Food and Drug Administration (FDA) has approved Susvimo® (ranibizumab injection) 100 mg/...

February 05, 2025 | Wednesday | News
Roche's PATHWAY® Anti-HER2 Test Gains FDA Approval to Identify HER2-Ultralow Metastatic Breast Cancer Patients for ENHERTU® Treatment

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced  that the U.S. Food and Drug Administration (FDA) has approved a label expansion for the PATHWAY® ant...

February 03, 2025 | Monday | News
Celltrion Announces FDA Approval of AVTOZMA® (CT-P47) as Biosimilar to ACTEMRA® for Multiple Indications

Celltrion announced that the U.S. Food and Drug Administration (FDA) has approved AVTOZMA® (CT-P47, tocilizumab-anoh) in both an intravenous (IV) ...

January 31, 2025 | Friday | News
Mesoblast Advances U.S. Commercial Launch of Ryoncil® for Pediatric SR-aGvHD, with Key Milestones Ahead

Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases,  provided an update on the progres...

January 31, 2025 | Friday | News
Vertex Pharmaceuticals Announces FDA Approval of JOURNAVX™ (Suzetrigine) for Acute Pain Treatment

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced that the U.S. Food and Drug Administration (FDA) has approved JOURNAVX™ (suzet...

January 31, 2025 | Friday | News
Roche Announces Positive Overall Survival Results for Itovebi™ in Advanced Breast Cancer

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced positive topline results from the overall survival (OS) analysis of the phase III INAVO120 study investigating...

January 29, 2025 | Wednesday | News
Merck’s WELIREG® (belzutifan) Accepted for Priority Review by FDA for Advanced Pheochromocytoma and Paraganglioma

 Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced the U.S. Food and Drug Administration (FDA) has accepted for prior...

January 28, 2025 | Tuesday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close